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Abstract 
Persistent depressive disorder or dysthymia is a recurrent depressive disorder 
with no clearly demarcated episodes. Onset is insidious and can occur in ado-
lescence or adulthood. Dysthymia frequently remains unrecognized and un-
diagnosed for years. Co-morbid major depression, anxiety, personality, so-
matoform and substance abuse disorders are common. Symptoms center on 
sad mood, pessimism and hopelessness. Sufferers experience significant func-
tional impairment and are at risk of death by suicide. Those most at risk are 
female, unmarried, live in high income countries and have family histories of 
depression. Screening instruments include the Cornell Dysthymia Rating Scale 
(CDRS). Typical treatments are antidepressant medications and cognitive be-
havioral analysis system of psychotherapy (CBASP). This paper provides health 
professionals with an overview of assessment and treatment approaches in 
dysthymia. 
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1. Introduction 
Living with the unrelenting burden of persistent depressive disorder (PDD) or 
dysthymia leaves those who are afflicted feeling despondent and hopeless most 
of their lives. PDD or dysthymia is a recurrent, prolonged depressive disorder 
with no clearly demarcated episodes. Dysthymia, from the Greek “ill humor” or 
“bad state of mind” is understudied, often undertreated and can lead to high 
rates of death by suicide (Cristancho, Kocsis & Thase, 2012; Ishizaki & Mimura, 
2011; Niculescu & Akiskal, 2001). Existing research has focused on diagnosing 
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dysthymia and evaluating treatment with antidepressant medication and psy-
chotherapy. Most of this work has been directed to physicians. However, health 
professionals from a variety of different settings can expect to encounter people 
struggling to cope with dysthymia in their practice. Raising awareness about 
dysthymia among all members of health care teams can make an important dif-
ference in recognizing the disorder and initiating appropriate referrals. Geared 
to a multidisciplinary audience, this article presents an explanation of dysthymia 
by explaining current assessment and treatment approaches. 
2. Assessment 
2.1. Diagnosis 
The process of diagnosing PDD or dysthymia is not straightforward. For many 
individuals, a constant battle with low grade depression, sad moods and a lack of 
excitement has become a way of life. Once known as neurotic depression, in 
1980 the diagnosis of dysthymia was introduced into the third edition of the Di-
agnostic and Statistical Manual of Mental Disorders, the DSM-111 (American 
Psychiatric Association, 1980). At that time, the depressive symptoms of dyst-
hymia were characterized as less severe but of longer duration than those of ma-
jor depressive disorder (MDD). Dysthymia was associated with disturbances in 
appetite, sleep, energy, concentration, self-esteem and feelings of hopelessness 
(American Psychiatric Association, 1980).  
Later, in 2000, the diagnosis of chronic depressive disorder, where symptoms 
of depressed mood, loss of interest in daily activities and impaired social, occu-
pational or educational function persisted longer than two years was introduced 
into the DSM-IV-TR (American Psychiatric Association, 2000). Today, the DSM-5 
consolidated the diagnoses of dysthymia and chronic depressive disorder into 
persistent depressive disorder PDD, often still identified as dysthymia (Ameri-
can Psychiatric Association, 2013).  
Dysthymia is diagnosed in adults when individuals have not been free of their 
depressive symptoms for longer than 2 months over a 2-year period and have 
not experienced an episode of major depression or mania. In children and ado-
lescents, the criteria span a 1-year period. However, two key features of dysthy-
mia are first that no clearly demarcated episodes occur and second that the du-
ration is prolonged and can occur both below and above the stipulated 1 or 
2-year cut-off points (Uher, 2014). Some people may only seek help after ex-
periencing depressive symptoms for decades rather than just after 2 years (Hel-
lerstein, 2014).  
2.2. Co-Morbidity  
Dysthymia frequently co-occurs with other psychiatric conditions. Many peo-
ple with dysthymia also develop major depressive disorder MDD, a condition 
known as double depression (Dunner, 2005; Keller, Hirschfeld, & Hanks, 1997; 
Klein, Shankman, & Rose, 2006). MDD is characterized by depressed mood, loss 
of interest or pleasure, weight gain or loss, insomnia or hypersomnia, psycho-
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motor agitation or retardation, fatigue, feelings of worthlessness, difficulty con-
centrating and suicidal ideation most of the day, nearly every day during the 
same two week period (American Psychiatric Association, 2013). The disorders 
differ in that the most common symptoms of dysthymia are low self-esteem and 
pessimism; while the most common symptoms of MDD are neuro-vegetative 
signs such as sleep or appetite disturbances (Gwirtzman, Blehar, McCullough, 
Kocsis, & Prien, 1997). In both MDD and dysthymia, people experience feelings 
of hopelessness and are unable to find relief from their despair. When double 
depression is present, these feelings of hopelessness intensify (Joiner, Cook, Hersen, 
& Gordon, 2007). Most people with dysthymia develop at least one episode of 
MDD in their lifetime (Klein, Schwartz, Rose, & Leader, 2000). 
Further, anxiety disorders are often present in children, adolescents (Masi, 
Millepiedi, Mucci, Pascale, Perugi, & Akiskal, 2003) and adults (Pini, Cassano, 
Simonini, Savino, Russo, & Montgomery, 1997; Sansone & Sansone, 2009; Shank-
man & Klein, 2002) with dysthymia. Given the frequency of co-occurring anxi-
ety and dysthymia, Niculescu and Akiskal proposed a division of dysthymia into 
two distinct endophenotypes or sub types: anxious dysthymia (formerly known 
as atypical) and non-anxious or anergic dysthymia (formerly known as typical) 
(Niculescu & Akiskal, 2001). Anxious dysthymia is hypothesized as having an 
association with low serotonin, which regulates mood, calmness and composure 
when dealing with stressful events. When people with anxious dysthymia per-
ceive stress, their symptoms of insecurity, low self-esteem and restlessness exac-
erbate or worsen (Niculescu & Akiskal, 2001).  
Non-anxious or anergic dysthymia is hypothesized as having an association 
with low dopamine, which is involved in motivation, thinking, and motor activi-
ties (Niculescu & Akiskal, 2001). When people with anergic dysthymia perceive 
they have failed, they are likely to demonstrate more intense manifestations of 
sluggish reactivity, low drive, low energy and psychomotor inertia. In combina-
tion with the extended duration of their depressive illness, this subtyping of 
symptoms suggests that these traits may have evolved as a way for individuals to 
cope with the stresses and failures they believe they face (Niculescu & Akiskal, 
2001).  
Personality disorders, somatoform disorders, and substance abuse disorders 
also commonly co-occur with dysthymia (Sansone & Sansone, 2009). Personality 
disorders, such as depressive personality disorder, which is characterized by 
self-critical tendencies, introversion and a gloomy, negative outlook can appear 
very similar to dysthymia (Ishizaki & Mimura, 2011). Similarly somataform dis-
orders, which are characterized by physical symptoms that suggest a general 
medical condition, but are not fully explained by that condition, can overlap 
with dysthymia (Feder, n.d.). For example, unexplained back pain, headaches 
and muscle soreness can be associated with both conditions (Feder, n.d.). High 
levels of alcohol dependence have been associated with dysthymia (Diaz, Horton 
& Weiner, 2012). People who develop dysthymia before the age of 21 are pre-
disposed to developing both comorbid personality disorders and substance use 
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disorders (Halverson, 2015).  
As a non-episodic illness, dysthymia is difficult to recognize (Avrichir & Elkis, 
2002; Weissman & Klerman, 1977). Health professionals may perceive sufferers 
as people who demonstrate sarcastic, nihilistic, morose, demanding and plain-
tive behaviors rather than as people experiencing prolonged and profound sad-
ness (Spanemberg & Juruena, 2004). Having endured their illness for extended 
periods of time, people with dysthymia can project pessimism, gloominess and a 
lack of self-confidence (Akiskal, 1983). Rather than seeking help for a mood dis-
turbance, they may describe feeling generally unwell, lethargic and chronically 
fatigued (Akiskal, 1996; Brunello, Akiskal, Boyer, Gessa, Howland, Langer et al., 
1995). Consequently, adequate assessment of dysthymia may not occur (Spanem-
berg & Juruena, 2004). In 2009, Sansone and Sansone described people with 
dysthymia as forlorn and overlooked a representation that continues to be ap-
plicable (Sansone & Sansone, 2009). 
2.3. Severity 
The chronic nature of dysthymia can cause greater impairment to functioning 
than acute depression (Sandhu, Ghosh, & Dellenbaugh, 2016). Dysthymia suf-
ferers are less likely to work full-time, they receive income supplements more 
often and they are more likely to report interference with social activities as a 
result of emotional and physical problems (Hellerstein, Agosti, Bosi, & Black, 
2010). For those with co-occurring personality disorders, dysthymia imposes 
significant additional impairment to their psychosocial functioning (Hellerstein, 
Skodol, Petkova, Xie, Markowitz et al., 2010) 
People with dysthymia have a 71.4% risk of relapsing into another period of 
chronic depression (Klein, Shankman, & Rose, 2006). When suicidal ideation 
occurs in one episode of depression, it is likely to recur in subsequent episodes 
(Williams, Crane, Barnhofer, van der Does, & Segal, 2006). It is important to 
emphasize that individuals with dysthymia have been found to be more likely to 
attempt suicide and to be hospitalized than those with major depression (Klein, 
Schwartz, Rose, & Leader, 2000). As many as 51% of individuals being treated 
for persistent depression continued to experience suicidal ideation after 32 months 
(Young, Klap, Shoai, & Wells, 2008). Clearly, when health professionals deter-
mine that individuals in their care are experiencing depression, it is critical to 
assess for suicidal ideation.  
2.4. Prevalence 
Dysthymia, a long term “smouldering mood disturbance” with infrequent and 
transient periods of normal mood is common in the community, primary care 
and mental health settings (Sansone & Sansone, 2009). The disorder has been es-
timated to affect approximately 1.5 percent of the adult population, with 49.7% 
of these cases classified as severe (Kessler, Chiu, Demler, & Walters, 2005). Only 
67.5% of those with the disorder are receiving treatment and for 27.5% of those 
individuals, the treatment is only minimally adequate (Wang, Lane, Olfson, Pin-
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cus, Wells, & Kessler, 2005). As many as 7% of primary care patients and 33% of 
psychiatric outpatients are believed to be living with dysthymia (Sansone & 
Sansone, 2009).  
Dysthymia follows a chronic course and can have an early and insidious onset, 
often in adolescence (Halverson, 2015). In adolescents, approximately 11% of 13 
to 18 year olds experienced major depressive disorder/dysthymia, with 3.3 % 
of these considered seriously debilitating (Merikangas, He, Burstein, Swanson, 
Avenevoli, Cui et al., 2010).  
2.5. Etiology 
While the cause of the disorder may not be clear, physiologic abnormalities have 
been associated with dysthymia. For example, polysomnography or sleep studies 
have indicated irregularities such as shorter periods of dreamless sleep (non- 
rapid eye movement NREM sleep); taking a shorter period of time to enter rapid 
eye-movement REM sleep (latency); and increased frequency of rapid eye move-
ments (density) during REM sleep (Abad & Guilleminault, 2005). Interleukin-1, 
a group of 11 cytokines which plays a central role in the regulation of immune 
and inflammatory responses can be elevated (Anisman, Ravindran, Griffiths, & 
Merali, 1999). Further, serotonin, a neurotransmitter, can have a lower maxi-
mum rate of uptake (Ravidran, Chudzik, Bialik et al., 1994). In females with 
dysthymia, platelet monoamine oxidase activity, which is needed for neuro-
transmissions, can be lower (Tripodianakis, Markianos, Sarantidis, Spyropoulou, 
Taktikou, & Bistolaki, 1998). 
As has been demonstrated in MDD, increased neural activity, or functional 
connectivity within the default mode network (DMN) of the brain may be im-
portant in the pathophysiology of dysthymia (Posner, Hellerstein, Gat, Mech-
ling, Klahr, Wang et al., 2013). The DMN is a collection of brain regions that are 
less active during goal-directed behaviors and more active when in a resting state 
(Posner et al.). When Posner, Hellerstein and colleagues examined the effects of 
antidepressant medications on dysthymia, they identified that antidepressants 
normalized DMN connectivity, suggesting a causal pathway (Posner et al.). 
Psychosocially, it is possible that severe events in childhood and stressful life 
events such as the loss of a partner or serious illness may predispose people to 
dysthymia (Wu, Wang, Wei, Zhang, Shi, Gao et al., 2013). Those with family 
histories of major depression, bipolar disorder, dysthymia and personality disord-
ers are particularly susceptible (Ishizaki & Mimura, 2011; Lizardi & Klein, 2000). 
Women (Charlson, Ferrari, Flaxman, & Whiteford, 2013) and unmarried people 
are at greater risk (Markkula, Suvisaari, Pirkola, Pena, Saarni, & Suvisaari, 2015). 
Dysthymia is more prevalent in in high-income countries than in low and middle 
income countries (Gurege, 2011). Females experiencing dysthymia frequently have 
a history of thyroid dysfunction (Scott, Baker, & Eccleston, 1988).  
3. Cornell Dysthymia Rating Scale (CDRS) 
As the previous discussion has illustrated, a significant number of people are 
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living with the debilitating effects of dysthymia and are not functioning to their 
full potential. By screening for the disorder, particularly in familiar primary care 
settings where people are accustomed to coming for treatment, health profes-
sionals can help identify those who are suffering. 
The Cornell Dysthymia Rating Scale (CDRS), first developed by Mason and 
colleagues in 1993 continues to be an efficient screening instrument (Cohen, 1997; 
Hellerstein, Batchelder, Lee, & Borisovskaya, 2002; Kannappan & Bai, 2007; 
Lam, Michalak & Swinson, 2005; Mason, Kocsis, Leon, Thompson, Frances et 
al., 1993). The CDRS is a simple straightforward questionnaire that all members 
of health care teams can readily implement with the people in their care. The 
CDRS is a 20-item scale developed specifically to assess frequency and severity of 
symptoms of dysthymia over the previous week (Mason et al.). Items are scored 
on a 0 - 4 basis, with a total score range of 0 - 80, where higher scores indicate 
greater severity of symptoms. 
The scale can be either self or clinician rated and refers to current and recent 
symptoms rather than normal premorbid periods, thus making it particularly 
suitable to assessing the chronic and recurring symptoms of dysthymia (Cohen, 
1997). The strength of the CDRS’s severity range scores, concurrent validity and 
content validity indicate it is a valuable instrument (Hellerstein et al., 2002). Ad-
ditionally, because the CDRS is sensitive to change it can serve as a useful tool 
for monitoring response to treatment (Lam et al., 2005). The CDRS is freely 
available in the public domain and no training is required to use the tool. 
4. Treatment Approaches 
4.1. Pharmacology and Psychotherapy 
Studies have consistently reported the superiority of treating dysthymia with a 
combined approach of both antidepressant medication and psychotherapy (Jobst, 
Brakemeier, Buchheim, Caspar, Cuijpers, Ebmeir et al., 2016; Keller, McCul-
lough, Klein, Arnow, Dunner et al., 2000). It is beyond the scope of this article to 
provide more than a brief explanation of these approaches. Although many groups 
of health professionals are not directly involved with either medication pre-
scribing and administrating or conducting psychotherapy themselves, having a 
rudimentary understanding of available treatment can be useful when referring 
people for the help they need. 
In their seminal examination of the treatment of chronic depression, Keller, 
McCullough, Klein and colleagues randomly assigned patients to one of three treat- 
ment groups: a cognitive behavioral-analysis system of psychotherapy (CBASP); 
administration of the antidepressant nefazodone (serzone); or a combination of 
the two (Keller, McCullough, Klein, Arnow, Dunner, Gelenberg et al., 2000). 
While less than half of the patients in the individual groups responded, nearly 
three-quarters of those in the combined group responded favorably to the com-
bined treatment approach.  
The psychotherapeutic approach these researchers implemented, the cognitive 
behavioral analysis system of psychotherapy (CBASP) was developed specifically 
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for people experiencing chronic depression. This approach used a structured, 
directive “social problem-solving algorithm to address interpersonal difficulties … 
[resulting in] patients learn[ing] how their cognitive and behavioral patterns 
produce and perpetuate their interpersonal problems … [thereby] remedy[ing] 
maladaptive patterns of interpersonal behavior (p. 1462). The approach was fully 
explained in McCullough’s 1999 text: Treatment for chronic depression: cogni-
tive behavioral analysis system of psychotherapy (CBASP) (McCullough, 1999). 
Although the strikingly positive benefits of CBASP were not duplicated in a later 
study (Kocsis, Gelenberg, Rothbaum, Klien, Trivedi, & Manber, 2009), this unique 
type of cognitive behavior therapy, with its focus on the non-episodic nature of 
dysthymia, continues to be viewed as an important treatment approach (McCul- 
lough, Schramm, & Penberthy, 2015; Negt, Brakemeier, Michalak, Winter, Bleich, 
Kahl et al., 2016). 
In their meta-analysis of research directly comparing the efficacy of psycho-
therapy and pharmacotherapy in treating depression, Cuijpers and colleagues 
demonstrated that psychotherapy was more efficacious than pharmacotherapy 
with tricyclic antidepressants (Cuijpers et al., 2013). On the other hand, Kriston 
and colleagues’ analysis of treatments specifically for persistent depressive indi-
cated that while psychotherapy with medication outperformed medication alone 
in chronic major depression, it was not more effective in dysthymia (Kriston, 
Wolff, Westphal, Hölzel, & Härter, 2014). The benefits of antidepressant medi-
cations, which can determined after only a few weeks, can be more rapidly effec-
tive that those experienced in therapy sessions, most of which extend over several 
months (Thase, Friedman, Biggs, Wisniewski, Trivedi, Luther et al., 2007). Yet, 
intolerance to medications can make therapy a fitting choice for many people. 
These kinds of conflicting reports illustrate how our understanding of dysthymia 
as a unique and non-episodic depression is continually evolving. 
Straddling both approaches, Uher suggested initiating treatment with medica-
tion and then following up with therapy (Uher, 2014). For example, antidepres-
sants with strong efficacy and good tolerability include selective serotonin reup-
take inhibitors (SSRIs) such as sertraline/zoloft; monoamine oxidase inhibitors 
(MAOI) such as moclobemide/manerix or phenelzineis/nardil; or tricyclic anti-
depressants (TCAs) such as imipramine/tofranil. Once the medications have 
achieved at least a partial response, then therapy can be individualized to address 
symptoms associated with depression (Uher, 2014). 
4.2. Alternative Therapies 
Alternative therapies have also been considered in the treatment of dysthymia. St 
John’s wort/hypericum, often viewed by the lay public as an herbal remedy, has 
been found somewhat effective in minor depression but less so in dysthymia 
(Randløv, Mehlsen, Thomsen, Hedman, von Fircks et al., 2006). Cautions asso-
ciated with St. John’s wort include potential interactions with blood-thinning 
drugs, birth control pills, chemotherapy, HIV/AIDS medications and antide-
pressants (Mayo Clinic, n.d.).  
S. Melrose 
 
8 
Likewise, exercise has been found to be beneficial as an adjunct to treatment 
of depression, but the effects are not well understood in dysthymia (Mead, Mor-
ley, Campbell, Greig, McMurdo, & Lawlor, 2010). Lifestyle modifications, also 
known as lifestyle medicine, where people adopt healthier patterns of eating, 
physical activity, relaxation/sleep, substance use and social interaction are be-
lieved to improve depression (Sarris, O’Neil, Coulson, Schweitzer, & Berk, 2014). 
Professionals from all health disciplines can invite clients in their practice to 
consider making changes in these areas.  
4.3. Future Directions 
Positive outcomes for treating dysthymia may not be immediate and trying dif-
ferent combinations of medications, therapies and lifestyle modifications may be 
necessary. Responses to treatment, like symptoms, will vary among individuals. 
Duration of symptoms, support systems, coping mechanisms and current life 
circumstances can all impact recovery. However, research continues to offer hope 
for relief from the debilitating symptoms of dysthymia. Levkovitz and colleagues’ 
meta-analysis of the efficacy of treating dysthymia with antidepressants concluded 
that antidepressant therapy was significantly more effective than placebo in 17 
different studies (Levkovitz, Tedeschini, & Papakostas, 2011).  
Plans to implement a meta-analysis of existing clinical trials which explored 
the efficacy of CBASP therapy in combination with medication are underway 
(Furukawa, Schramm, Weitz, Salanti, Efthimiou, Michalak et al., 2016). This 
upcoming review is framed from a differential therapeutics perspective and will 
seek individual participant data from each of the trials reviewed, allowing find-
ings to be matched to specific subgroups of patients.  
5. Conclusion 
In summary, this paper provided an overview of persistent depressive disorder 
or dysthymia, explaining assessment approaches in relation to DSM-5 criteria, 
symptoms, comorbidity, etiology, severity and prevalence. People with dysthymia 
experience sad moods and feel pessimistic and hopeless to the extent that they 
are not able to function. Many are at high risk for death by suicide and health 
professionals should routinely assess for suicidal ideation.  
As a non-episodic, insidious and difficult to recognize disorder, dysthymia can 
first appear in adolescence and remain untreated for years. Women and those 
who are unmarried are most at risk. Clinician or self-reported scores on the 
Cornell Dysthymia Rating Scale (CDRS) can immediately communicate people’s 
views about the severity of their illness. 
Living with sadness for extended periods of time can leave people suffering 
from dysthymia resigned to the idea that things are unlikely to change for them. 
Antidepressant medications offer some relief. However, cognitive behavioral 
analysis system of psychotherapy (CBASP) is also emerging as an effective treat-
ment. This paper calls for health professionals to integrate dysthymia assess-
ments and referral processes into their practice. Doing so may begin to instil 
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needed hope to the many individuals with dysthymia who are simply enduring 
rather than enjoying their lives. 
References 
Abad, V. C., & Guilleminault, C. (2005). Sleep and Psychiatry. Dialogues in Clinical 
Neuroscience, 7, 291-303.  
Akiskal, H. S. (1983). Dysthymic Disorder: Psychopathology of Double-Blind Long Term 
Extension of Several of These Proposed Chronic Depressive Subtypes. American Jour-
nal of Psychiatry, 140, 11-20. https://doi.org/10.1176/ajp.140.1.11 
Akiskal, H. S. (1996). Dysthymia as a Temperamental Variant of Affective Disorder. 
European Psychiatry, 11, 117s-22s. https://doi.org/10.1016/0924-9338(96)85185-6 
American Psychiatric Association (1980). Diagnostic and Statistical Manual of Mental 
Disorders (3rd ed.). Washington DC: Author. 
American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental 
Disorders(4th ed., text rev.). Washington DC: Author. 
American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental 
Disorders (5th ed.). Washington DC: Author. 
https://doi.org/10.1176/appi.books.9780890425596 
Anisman, H., Ravindran, A., Griffiths, J., & Merali, Z. (1999). Interleukin-1 Beta Produc-
tion in Dysthymia Before and After Pharmacotherapy. Biological Psychiatry, 46, 1649- 
1655. https://doi.org/10.1016/S0006-3223(99)00211-5 
Avrichir, B., & Elkis, H. (2002). Prevalence and Underrecognition of Dysthymia among 
Psychiatric Outpatients in São Paulo, Brazil. Journal of Affective Disorder, 69, 193-199.  
https://doi.org/10.1016/S0165-0327(01)00342-1 
Brunello, N., Akiskal, H., Boyer, P., Gessa, G., Howland, R., Langer, S. et al. (1995). Dyst-
hymia: Clinical Picture, Extent of Overlap with Chronic Fatigue Syndrome, Neuro-
pharmacological Considerations, and New Therapeutic Vistas. Journal of Affective 
Disorders, 52, 275-290. https://doi.org/10.1016/S0165-0327(98)00163-3 
Charlson, F., Ferrari, A., Flaxman, A., & Whiteford, H. (2013). 1. The Epidemiological 
Modelling of Dysthymia: Application for the Global Burden of Disease Study 2010. 
Journal of Affective Disorders, 151, 111-120. https://doi.org/10.1016/j.jad.2013.05.060 
Cristancho, M., Kocsis, J., & Thase, M. (2012). Dysthymia Disorder and Other Chronic 
Depressions. Focus the Journal of Lifelong Learning in Psychiatry, 10, 422-427.  
https://doi.org/10.1176/appi.focus.10.4.422 
Cohen, J. (1997). Assessment and Treatment of Dysthymia: The Development of the 
Cornell Dysthymia Rating Scale. European Psychiatry, 12, 190-193. 
https://doi.org/10.1016/S0924-9338(97)89103-1 
Cuijpers, P., Sijbrandij, M., Koole, S. L., Andersson, G., Beekman, A. T., & Reynolds, C. F. 
(2013). The Efficacy of Psychotherapy and Pharmacotherapy in Treating Depressive 
and Anxiety Disorders: A Meta-Analysis of Direct Comparisons. World Psychiatry, 12, 
137-148. https://doi.org/10.1002/wps.20038 
Diaz, N., Horton, E., & Weiner, M. (2012). Dysthymia, Major Depression, and Double 
Depression among Individuals Receiving Substance Abuse Treatment. Health, 4, 1229- 
1237. https://doi.org/10.4236/health.2012.412181 
Dunner, D. (2005). Dysthymia and Double Depression. International Review of Psychia-
try, 17, 3-8. https://doi.org/10.1080/09540260500064983 
Feder, A. (n.d.) Chapter 3532: Somatization. General Medicine Clinics, Columbia Medi-
cal School Ambulatory Syllabus.  
S. Melrose 
 
10 
http://www.medicineclinic.org/AmbulatorySyllabus4/NEW%20somatization.htm  
Furukawa, T., Schramm, E., Weitz, E. S., Salanti, G., Efthimiou, O., Michalak, J. et al. 
(2016). Cognitive-Behavioural Analysis System of Psychotherapy (CBASP), a Drug, or 
Their Combination: Differential Therapeutics for Persistent Depressive Disorder: A 
Study Protocol of an Individual Participant Data Network Meta-analysis. BMJ Open, 6, 
e011769. https://doi.org/10.1136/bmjopen-2016-011769 
Gwirtzman, H., Blehar, M., McCullough, J., Kocsis, J., & Prien, R., (1997). Standardized 
Assessment of Dysthymia. Report of a National Institute Mental Conference. Psy-
chopharmacological Bulletin, 33, 3-11.  
Gurege, O. (2011). Dysthymia in a Cross-cultural Perspective. Current Opinion in Psy-
chiatry, 24, 67-71. https://doi.org/10.1097/YCO.0b013e32834136a5 
Halverson, J. (2015). Dysthymic Disorder: Background, Etiology, Epidemiology. Med-
scape. http://emedicine.medscape.com/article/290686-overview  
Hellerstein, D., Batchelder, S., Lee, A., & Borisovskaya, M. (2002). Rating Dysthymia: An 
Assessment of the Construct and Content Validity of the Cornell Dysthymia Rating 
Scale. Journal of Affective Disorders, 71, 85-96.  
https://doi.org/10.1016/S0165-0327(01)00371-8 
Hellerstein, D., Agosti, V., Bosi, M., & Black, S. (2010). Impairment in Psychosocial 
Functioning Associated with Dysthymic Disorder in the NESARC Study. Journal of 
Affective Disorders, 127, 84-88. https://doi.org/10.1016/j.jad.2010.04.013 
Hellerstein, D. J., Skodol, A. E., Petkova, E., Xie, H., Markowitz, J. C., Yen, S., McGlashan, 
T. H. et al. (2010). The Impact of Comorbid Dysthymic Disorder on Outcome in Per-
sonality Disorders. Comprehensive Psychiatry, 51, 449-457.  
https://doi.org/10.1016/j.comppsych.2009.11.002 
Hellerstein, D. (2014). Dysthymic Disorder (Persistent Depressive Disorder). Encyclope-
dia of Psychopharmacology, Berlin: Springer.  
Ishizaki, J., & Mimura, M. (2011). Dysthymia and Apathy: Diagnosis and Treatment. De-
pression Research and Treatment, 2011, Article ID: 893905.  
Jobst, A., Brakemeier, E., Buchheim, A., Caspar, F., Cuijpers, P., Ebmeier, K. et al. (2016). 
European Psychiatric Association Guidance on Psychotherapy in Chronic Depression 
across Europe. European Psychiatry, 33, 18-36.  
https://doi.org/10.1016/j.eurpsy.2015.12.003 
Joiner, T., Cook, J., Hersen, M., & Gordon, K. (2007). Double Depression in Older Adult 
Psychiatric Outpatients: Hopelessness as a Defining Feature. Journal of Affective Dis-
orders, 101, 235-238. https://doi.org/10.1016/j.jad.2005.03.019 
Kannappan, R., & Bai, R. (2007). Cognitive Behaviour Therapy as an Adjunct to Drug 
Therapy in the Treatment of Dysthymic Disorder. Journal of the Indian Academy of 
Applied Psychology, 33, 195-200. 
Keller, M., Hirschfeld, R., & Hanks, D. (1997) Double Depression: A Distinctive Subtype 
of Unipolar Depression. Journal of Affective Disorders, 45, 65-73. 
https://doi.org/10.1016/S0165-0327(97)00060-8 
Keller, M., McCullough, J., Klein, D., Arnow, B., Dunner, D., Gelenberg, A. et al. (2000). 
A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psycho-
therapy, and Their Combination for the Treatment of Chronic Depression. New Eng-
land Journal of Medicine, 342, 1462-1470.  
https://doi.org/10.1056/NEJM200005183422001 
Kessler, R., Chiu, W., Demler, O., & Walters, E. (2005). Prevalence, Severity, and Comor-
bidity of Twelve-Month DSM-IV Disorders in the National Comorbidity Survey Rep-
lication (NCS-R). Archives of General Psychiatry, 62, 617-627.  
S. Melrose 
 
11 
https://doi.org/10.1001/archpsyc.62.6.617 
Klein, D., Schwartz, J., Rose, S., & Leader, J. (2000). Five-Year Course and Outcome of 
Dysthymic Disorder: A Prospective, Naturalistic Follow-Up Study. American Journal 
of Psychiatry, 157, 931-939. https://doi.org/10.1176/appi.ajp.157.6.931 
Klein, D., Shankman, S., & Rose, S. (2006). Ten-Year Prospective Follow-Up Study of the 
Naturalistic Course of Dysthymic Disorder and Double Depression. American Journal 
of Psychiatry, 163, 872-880. https://doi.org/10.1176/ajp.2006.163.5.872 
Kocsis, J., Gelenberg, A., Rothbaum, B., Klien, D., Trivedi, M., Manber, R. et al. (2009). 
Cognitive Behavioral Analysis System of Psychotherapy and Brief Supportive Psycho-
therapy for Augmentation of Antidepressant Nonresponse in Chronic Depression: The 
REVAMP Trial. Archives of General Psychiatry, 66, 1178-1188.  
https://doi.org/10.1001/archgenpsychiatry.2009.144 
Kriston, L., Wolff, A., Westphal, A., Hölzel, L., & Härter, M. (2014). Efficacy and Accept-
ability of Acute Treatments for Persistent Depressive Disorder: A Network Meta- 
Analysis. Depression and Anxiety, 31, 621-630. https://doi.org/10.1002/da.22236 
Lam, R., Michalak, E., & Swinson, R. (2005). Assessment Scales in Depression, Mania and 
Anxiety. London: Taylor and Francis.  
http://files3.moshaverfa.com/en/pdf/Assessment/2005_-_Assessment_scales_in_depres
sion,_mania_and_anxiety_-_Lam,_Michalak,_Swinson.pdf  
Levkovitz, Y., Tedeschini, E., & Papakostas, G. (2011). Efficacy of Antidepressants for 
Dysthymia: A Meta-Analysis of Placebo-Controlled Randomized Trials. Journal of 
Clinical Psychiatry, 72, 509-514. https://doi.org/10.4088/JCP.09m05949blu 
Lizardi, H., & Klein, D. (2000). Parental Psychopathology and Reports of the Childhood 
Home Environment in Adults with Early-Onset Dysthymic Disorder. Journal of Nerv-
ous and Mental Disease, 188, 63-70.  
https://doi.org/10.1097/00005053-200002000-00001 
Markkula, N., Suvisaari, J., Pirkola, S., Pena, S., Saarni, S., & Suvisaari, J. (2015). Preva-
lence and Correlates of Major Depressive Disorder and Dysthymia in an Eleven-Year 
Follow-Up—Results from the Finnish Health 2011 Survey. Journal of Affective Disor-
ders, 173, 73-80. https://doi.org/10.1016/j.jad.2014.10.015 
Masi, G., Millepiedi, S., Mucci, M., Pascale, R. R., Perugi, G., & Akiskal, H. S. (2003). 
Phenomenology and Comorbidity of Dysthymic Disorder in 100 Consecutively Re-
ferred Children and Adolescents: Beyond DSM-IV. Canadian Journal of Psychiatry, 48, 
99-105.  
Mason, B., Kocsis, J., Leon, A., Thompson, S., Frances, A., Morgan, R. et al. (1993). 
Measurement of Severity and Treatment Response in Dysthymia. Psychiatric Annals, 
23, 625-631. https://doi.org/10.3928/0048-5713-19931101-09 
Mayo Clinic (n.d.). Persistent Depressive Disorder (Dysthymia). Alternative Medicine. 
http://www.mayoclinic.org/diseases-conditions/persistent-depressive-disorder/diagnos
is-treatment/treatment/txc-20166621  
McCullough, J. (1999). Treatment for Chronic Depression: Cognitive Behavioural Analy-
sis System of Psychotherapy (CBASP). New York: Guilford Publications.  
McCullough, J., Schramm, E., & Penberthy, K. (2015). CBASP: A Distinctive Treatment 
for Persistent Depressive Disorder. New York: Routledge.  
Mead, G., Morley, W., Campbell, P., Greig, C., McMurdo, M., & Lawlor, D. (2010). Exer-
cise for Depression. Cochrane Database of Systematic Reviews, CD004366.  
Merikangas, K., He, J., Burstein, M., Swanson, S., Avenevoli, Cui, L. et al. (2010). Lifetime 
Prevalence of Mental Disorders in US Adolescents: Results from the National Comor-
bidity Study-Adolescent Supplement (NCS-A). Journal of the American Academy of 
S. Melrose 
 
12 
Child Adolescent Psychiatry, 49, 980-989. https://doi.org/10.1016/j.jaac.2010.05.017 
Negt, P., Brakemeier, E., Michalak, J., Winter, L., Bleich, S., & Kahl, K. (2016). The 
Treatment of Chronic Depression with Cognitive Behavioral Analysis System of Psy-
chotherapy: A Systematic Review and Meta-Analysis of Randomized-Controlled Clini-
cal Trials. Brain and Behavior, 6, e00486. https://doi.org/10.1002/brb3.486 
Niculescu, A., & Akiskal, H. (2001). Proposed Endophenotypes of Dysthymia: Evolution-
ary, Clinical and Pharmacogenomic Considerations. Molecular Psychiatry, 6, 363-366. 
https://doi.org/10.1038/sj.mp.4000906 
Pini, S., Cassano, G., Simonini, E., Savino, M., Russo, A., & Montgomery, S. (1997). 
Prevalence of Anxiety Disorders Comorbidity in Bipolar Depression, Unipolar Depres-
sion and Dysthymia. Journal of Affective Disorders, 42, 145-153. 
https://doi.org/10.1016/S0165-0327(96)01405-X 
Posner, J., Hellerstein, D., Gat, I., Mechling, A., Klahr, K., Wang, Z. et al. (2013). Antide-
pressants Normalize the Default Mode Network in Patients With Dysthymia. JAMA 
Psychiatry, 70, 373-371. https://doi.org/10.1001/jamapsychiatry.2013.455 
Randløv, C., Mehlsen, J., Thomsen, C., Hedman, C., von Fircks, H. et al. (2006). The Effi-
cacy of St. John’s Wort in Patients with Minor Depressive Symptoms or Dysthymia—A 
Double-Blind Placebo-Controlled Study. Phytomedicine, 13, 215-221.  
https://doi.org/10.1016/j.phymed.2005.11.006 
Ravidran, A., Chudzik, J., & Bialik R. (1994). Platelet Serotonin Measures in Primary 
Dysthymia. American Journal of Psychiatry, 151, 1369-1371.  
https://doi.org/10.1176/ajp.151.9.1369 
Sandhu, R., Ghosh, S., & Dellenbaugh, T. (2016). Association between Dysthymic Dis-
ability and Disability, with Religiosity as Moderator. Activitas Nervosa Superior, 58, 
13-19.  
Sansone, R., & Sansone, L. (2009). Dysthymic Disorder: Forlorn and Overlooked. Psy-
chiatry, 6, 46-51. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719439/  
Sarris, J., O’Neil, A., Coulson, C. E., Schweitzer, I., & Berk, M. (2014). Lifestyle Medicine 
for Depression. BMC Psychiatry, 14, 107. https://doi.org/10.1186/1471-244X-14-107 
Scott, J., Baker, W., & Eccleston, D. (1988). The Newcastle Chronic Depression Study. Pa-
tient Characteristics and Factors Associated with Chronicity. British Journal of Psy-
chiatry, 152, 28-33. https://doi.org/10.1192/bjp.152.1.28 
Shankman, S., & Klein, D. (2002). The Impact of Comorbid Anxiety Disorders on the 
Course of Dysthymic Disorder: A 5-Year Prospective Longitudinal Study. Journal of 
Affective Disorders, 70, 211-217. https://doi.org/10.1016/S0165-0327(01)00302-0 
Spanemberg, L., & Juruena, M. (2004). Dysthymia: Historical/Nosological Characteristics 
and Its Relationship with Major Depressive Disorder. Revista de Psiquiatria do Rio 
Grande do Sul, 26, 300-301. 
http://www.scielo.br/scielo.php?pid=S0101-81082004000300007&script=sci_arttext&tl
ng=en  
Thase, M., Friedman, E., Biggs, M., Wisniewski, S., Trivedi, M., Luher, J. et al (2007). 
Cognitive Therapy versus Medication in Augmentation and Switch Strategies as Sec-
ond-step Treatments: A STAR*D Report. American Journal of Psychiatry, 164, 739- 
752. https://doi.org/10.1176/ajp.2007.164.5.739 
Tripodianakis, J., Markianos, M., Sarantidis, D., Spyropoulou, G., Taktikou, V., & Bisto-
laki, E. (1998). Platelet MAO Activity in Patients with Dysthymic Disorder. Psychiatry 
Research, 78, 173-178. https://doi.org/10.1016/S0165-1781(98)00011-0 
Uher, R. (2014). Persistent Depressive Disorder, Dysthymia, and Chronic Depression: 
Update on Diagnosis, Treatment. Psychiatric Times, 31, 46.  
S. Melrose 
 
13 
http://www.psychiatrictimes.com/special-reports/persistent-depressive-disorder-dysth
ymia-and-chronic-depression 
Weissman, M.M., & Klerman, G.L. (1977). The Chronic Depressive in the Community: 
Unrecognized and Poorly Treated. Comprehensive Psychiatry, 18, 523-532.  
https://doi.org/10.1016/S0010-440X(97)90002-X 
Williams, J., Crane, C., Barnhofer, T., van der Does, A., & Segal, Z. (2006). Recurrence of 
Suicidal Ideation across Depressive Episodes. Journal of Affective Disorders, 91, 189- 
194. https://doi.org/10.1016/j.jad.2006.01.002 
Wang, P., Lane, M., Olfson, M., Pincus, H., Wells, K., & Kessler, R. (2005). Twelve Month 
Use of Mental Health Services in the United States. Archives of General Psychiatry, 62, 
629-640. https://doi.org/10.1001/archpsyc.62.6.629 
Wu, W., Wang, Z., Wei, Y., Zhang, G., Shi, S., Gao, J. et al. (2013) Clinical Features of Pa-
tients with Dysthymia in a Large Cohort of Han Chinese Women with Recurrent Ma-
jor Depression. PLoS ONE, 8, e83490. https://doi.org/10.1371/journal.pone.0083490 
Young, A., Klap, R., Shoai, R., & Wells, K. (2008). Persistent Depression and Anxiety in 
the United States: Prevalence and Quality of Care. Psychiatric Services, 59, 1391-1398.  
https://doi.org/10.1176/ps.2008.59.12.1391 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Submit or recommend next manuscript to SCIRP and we will provide best 
service for you:  
Accepting pre-submission inquiries through Email, Facebook, LinkedIn, Twitter, etc.  
A wide selection of journals (inclusive of 9 subjects, more than 200 journals) 
Providing 24-hour high-quality service 
User-friendly online submission system  
Fair and swift peer-review system  
Efficient typesetting and proofreading procedure 
Display of the result of downloads and visits, as well as the number of cited articles   
Maximum dissemination of your research work 
Submit your manuscript at: http://papersubmission.scirp.org/ 
Or contact ojd@scirp.org 
